Report of adverse events of special interest (AESIs) for sintilimab plus a bevacizumab biosimilar (IBI305) in unresectable hepatocellular carcinoma. A multicenter study to investigate the role of ...
This following information is provided as guidance to assist Purdue instructors with ensuring digital instructional materials are accessible, according to the new ADA Title II Ruling, with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results